CRPOF News and Press, Ceapro Inc From 02/15/24

EDMONTON, Alberta, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“ Ceapro ” or the “ Company ”) is pleased to announce that it has mailed and filed a management information circular dated February 9, 2024 and related meeting material...

2023-12-14 08:15:55 ET More on Aeterna Zentaris, Ceapro, etc. Seeking Alpha’s Quant Rating on Aeterna Zentaris Historical earnings data for Aeterna Zentaris Financial information for Aeterna Zentaris Financial information for Ceapro For further...

TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“ Ceapro ”), two innovative biopharmaceutical development companies, today announced that they h...

– Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute – No adverse reactions observed, and study can continue as planned EDMONTON, Alberta, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”...

2023-11-29 12:56:56 ET More on Ceapro Financial information for Ceapro For further details see: Ceapro GAAP EPS of -C$0.01, revenue of C$2.62M

– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market – Technology development focused on the PGX pilot scale units – Q3 2023 sales of $2,619,000 vs $3,845,000 in Q3 2022 ;...

Addex Therapeutics Ltd (ADXN) is expected to report $-4 for Q3 2023 Eco Wave Power Global AB (publ) (WAVE) is expected to report for quarter end 2023-09-30 AmeraMex International, Inc. (AMMX) is expected to report for Q3 2023 iClick Interactive Asia Group Limited (ICLK) is expected to...

Study being led by Dr. Jean-Claude Tardif at the Montreal Heart Institute Screening of healthy subjects is now underway Phase 1-2a study to provide valuable insights into the safety and activity of avenanthramides in managing conditions related to inflammation EDMONTON, Albe...

Tekumo Inc (BCNN) is expected to report for Q3 2023 Diamcor Mining Inc (DMIFF) is expected to report for Q2 2024 American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Northwest Biotherapeutics Inc (NWBO) is expected to report for Q1 2024 Inspired Entert...

The RMR Group Inc. (RMR) is expected to report $0.46 for Q4 2023 Indra Sistemas ADR (ISMAY) is expected to report for Q3 2023 Ceapro Inc. (CRPOF) is expected to report for Q2 2024 Tuya Inc. American Depositary Shares each representing one Class A (TUYA) is expected to report $-0.02 fo...